Friday, 16 October 2026European Markets

ADC SIIC Stock Bullish By 26% In The Last 5 Sessions

Loading stream...

paris-based real estate investment company adc siic (aldv.pa) experienced an extraordinary 26.13% surge over five trading sessions from eur0.06 to eur0.07. despite this surge, shares remain 11.88% below their 52-week high of eur0.08.

contextualising adc siic's performance in the broader market

this fluctuation can be put in context with france's cac 40 index, which fell by 1.26% to eur7,312.84 last month. given adc siic is listed on this index, their dramatic stock increase during a general downward trend suggests specific factors have an influence over their shares.

market trends and potential investment opportunities

adc siic's stock performance may reflect current real estate market trends in paris and its suburbs, creating an opportunity for investors to capitalize on adc siic's position within this sector.

adc siic's profitability in spotlight

however, adc siic's profitability details paint an otherwise dim picture: trailing twelve month earnings per share (eps) has been negative at eur-0.01, while they reported a negative return on equity (roe) ratio of -1.87% over this same timeframe, signalling less return for capital provided by shareholders.

insight into adc siic's valuation

closer inspection of adc siic shows that its value exceeds both its 50-day moving average of eur0.07 and 200-day moving average of eur0.07. this indicates a steady upward trend despite fluctuations.

conclusion

in summary, adc siic stands out among other firms due to its rapid stock price appreciation during broader market downturns, coupled with its deep roots in parisian real estate and above-average moving averages despite its profitability issues. these characteristics make adc siic an attractive candidate for investors.

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com